

# New Hanover Radiation Oncology CDRP Grant U54 Update, Year 1



Patrick D. Maguire, MD  
RTOG Meeting, Philly  
June 18, 2010

Our Name Has Changed to:

# Coastal Carolina Radiation Oncology (CCRO)!!

- New Hanover Rad Onc (New Hanover County)
- Zimmer Cancer Center (NH County)
- South Atlantic Rad Onc (Brunswick County)
- Carteret General Hospital (Carteret County)
- Carolina East Medical Center (Craven County)



# CCRO U54 Grant Structure

- CCRO
  - Existing Sites Open for Clinical Trial Enrollment:
    - NHRO (Wilmington, NC)
    - Zimmer Cancer Center (Wilmington)
    - SARO (Supply)
  - Expansion of Clinical Trials to NEW Sites
    - CGH in Carteret (Morehead City) – open!
    - CEMC in Craven (New Bern) – in process
- Academic Partners
  - UNC - Dr. Larry Marks
    - H&N trial from U. Washington opened via UNC
  - WFUHC - Dr. Ed Shaw
    - Two new symptom management trials



# CCRO U54 - New Personnel

- Karen Johnson, BS
  - Grants Coordinator, NHRMC
  - From Duke Comprehensive Cancer Center
- Lynette Racco, RN, OCN
  - Nurse Manager of clinical research, NHRMC
- Amy Elder, RN, OCN
  - Clinical Research Nurse, NHRO
- Nicole Hudson, BA
  - New Patient Navigator (PN)



# Patient Navigation & Survivorship

## 10/1/9 – 6/1/10

- New PN, Nicole Hudson
- 14 of 39 patients (36%) underserved
- “Spin-off” grant from Lance Armstrong Foundation
  - LaSonia Melvin – coordinator (former PN)
  - ZCC @ NHRMC is 1 of 8 community centers selected to partner w/ UNC Center of Excellence in Survivorship



# CCRO U54 Year 1 Clinical Trial Successes

## **ASCO Clinical Trials Participation Award 2010**

- Nominated by RTOG... & we won!!
- 1 of 10 community oncology practices in U.S.
- Presented at ASCO June 6, 2010

## **PI-Initiated Trial Published in IJROBP**

- “Phase II Trial of Hyperfractionated Intensity Modulated Radiotherapy with Concurrent Weekly Cisplatin for Stage III and IVa Head & Neck Cancer”
- Front page article & photo, Wilm Star News 3/20/10



# CCRO U54 Treatment Trials 2010

- Prostate
  - 0232: brachy +/- 45 Gy for int risk
  - 0815: “high-dose” RT +/- hormones for int risk
  - 0534: RT to prostate bed +/-nodes +/- hormones
- Breast
  - 0413 (B39): APBI for early stage/young
- H&N
  - UW 3602: IMRT/CDDP +/- Tarceva for III/IVa
- Brain
  - 0614: Memantine vs. placebo for brain mets



# CCRO Treatment Trial Accruals 10/1/09 – 6/1/10

Trial #	Gen Pop	Underserved	Total
R0232	0	4	4
R0534	0	1	1
R0413 (B39)	0	0	0
R0614	2	2	4
R0815	0	0	0
UW3602	2	4	6
TOTALS	4	11 (73%)	15



# CCRO U54 Supportive Care & Prevention Trials June 2010

- Tumor Marker
  - FDI-15: CA125 & HE4 eval for pts w/ adnexal masses
- Symptom Management
  - WF-97405: Soy/Effexor for prostate pts on hormones
  - WF-97106: Arginmax for female pts who want to improve sexual function
- PI-Initiated (under final IRB review)
  - Phase II hypofx breast RT following oncoplastic BCS



# CCRO Prevention & Symptom Management Trial Accruals 10/1/09 – 6/1/10

Trial #	Gen Pop	Underserved	Total
FDI-15	22	13	35
WF-97405	1	0	1
WF-97106	0	3	3
Total	23	16 (41%)	39